Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 6, 2011, Pages 682-684

  Garcia Buey L ^a   Moreno Otero, R ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STEROID;

AUTOIMMUNE HEPATITIS; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT REJECTION; HUMAN; LETTER; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REMISSION; UNSPECIFIED SIDE EFFECT;

HEPATITIS, AUTOIMMUNE; HUMANS; MYCOPHENOLIC ACID;

EID: 80052010198     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04763.x     Document Type: Letter

References (12)

1. Baven-Pronk AMC, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34: 335-43.
2. Richardson PD, James PD, Ryder SD,. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5. (Pubitemid 30663373)
3. Devlin SM, Swain MG, Urbanski SJ, Burak KW,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-6. (Pubitemid 38801788)
4. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723-7. (Pubitemid 41038652)
5. Czaja AJ, Carpenter HA,. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819-25. (Pubitemid 41361901)
6. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802. (Pubitemid 47031057)
7. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-40.
8. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
9. Wolf DC, Bojito L, Facciuto M, Lebovics E,. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci 2009; 54: 2519-22.
10. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G,. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51: 156-60.
11. Sharzehi K, Huang MA, Schreibman IR, Brown KA,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588-92.
12. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naÍve patients. J Hepatol 2011 [Epub ahead of print].